Active Ingredient(s): Pexidartinib Hydrochloride
FDA Approved: * August 2, 2019

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Turalio Overview

Pexidartinib (trade name Turalio; development code name PLX-3397) is a CSF1R antagonist drug created by Plexxikon.[1][2] On 2 August 2019 it was approved by U.S. FDA for treatment of giant-cell tumor of the tendon sheath (GC-TS).[3][4] References ^ Adis Insight drug profile: Pexidartinib ^ Microglial Magic: Drug Wipes Them Out, New Set Appears (PLX3397) ^ "FDA approves first therapy for rare joint tumor". FDA. 2 August 2...

Read more Turalio Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pexidartinib

Recent Turalio Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pexidartinib Hydrochloride
  • Capsule: 200mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Turalio: (1 result)

Sorted by National Drug Code
  • 65597-402 Turalio 200 mg Oral Capsule by Daiichi Sankyo Inc.

Other drugs which contain Pexidartinib Hydrochloride or a similar ingredient: (1 result)

Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 8 April 2020.

We are committed to your privacy.

Copyright © 2005-2020 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA